The Cannabis Industry Needs Federal Reform For Marijuana Stocks To Trade Back UpThere are several reasons most marijuana stocks will trade up and down. As simple as that may seem, it is not, as there is more to it than can affect trading. For example, over the last several years, the cannabis sector has been declining and stagnating in trading. This created fear and issues for all shareholders. No one knew how the sector would bounce back with stable trading. Even when small jumps occurred, they were so sho ...

Group 1 - Medtronic reported quarterly earnings of $1.26 per share, exceeding the Zacks Consensus Estimate of $1.23 per share, and showing an increase from $1.23 per share a year ago, resulting in an earnings surprise of +2.44% [1] - The company achieved revenues of $8.58 billion for the quarter ended July 2025, surpassing the Zacks Consensus Estimate by 2.50%, and up from $7.92 billion year-over-year [2] - Medtronic has outperformed the S&P 500 with a share price increase of about 16.2% since the beginning of the year, compared to the S&P 500's gain of 9.7% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $1.33 on revenues of $8.73 billion, and for the current fiscal year, it is $5.55 on revenues of $35.29 billion [7] - The Zacks Industry Rank indicates that the Medical - Products industry is in the top 39% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8]

Industry Overview - Recent trading activity in marijuana stocks has increased, driven by discussions of federal reform by President Donald Trump, which is expected to advance the public sector and the industry as a whole [1][2] - There is growing speculation that the passage of federal reform will lead to consistent upward trading in the sector, boosting investor confidence [2] Company Highlights - **Verano Holdings Corp.**: Operates as a vertically integrated multi-state cannabis operator in the U.S. Recently announced the resignation of President Darren Weiss to pursue opportunities outside North America [4][5] - **Glass House Brands Inc.**: An integrated cannabis company operating in retail, wholesale biomass, and cannabis-related consumer packaged goods. Reported Q2 2025 earnings [5][6] - **Ayr Wellness Inc.**: Cultivates, manufactures, and retails cannabis products. Announced a restructuring support agreement with senior noteholders to ensure continued operations under new ownership [8][10] Financial Performance - **Glass House Brands Inc. Q2 2025 Results**: - Revenue of $59.9 million, an increase of 11% from $53.9 million in Q2 2024 and up 34% from $44.8 million in Q1 2025 [11] - Gross Profit of $31.9 million, compared to $28.7 million in Q2 2024 and $20.1 million in Q1 2025 [11] - Gross Profit Margin maintained at 53% [11] - Adjusted EBITDA of $18.1 million, up from $12.4 million in Q2 2024 and $4.4 million in Q1 2025 [11] - Positive Operating Cash Flow of $17.7 million, compared to $8.9 million in Q2 2024 and $2.5 million in Q1 2025 [11] - Equivalent Dry Pound Production of 230,748 pounds, a 54% year-over-year increase [11] - Cost per Equivalent Dry Pound of Production decreased by 39% to $91 per pound [11] - Cash, Restricted Cash, and Cash Equivalents balance of $44.2 million at quarter-end, up from $37.6 million at the end of Q1 2025 [11]

Group 1 - MacroGenics reported a quarterly loss of $0.57 per share, which was better than the Zacks Consensus Estimate of a loss of $0.59, and an improvement from a loss of $0.89 per share a year ago, resulting in an earnings surprise of +3.39% [1] - The company posted revenues of $22.24 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.73%, and showing significant growth from year-ago revenues of $10.8 million [2] - MacroGenics shares have declined approximately 48.9% since the beginning of the year, contrasting with a 10% gain in the S&P 500 [3] Group 2 - The earnings outlook for MacroGenics is mixed, with the current consensus EPS estimate for the coming quarter at -$0.40 on revenues of $26.77 million, and -$2.04 on revenues of $92.12 million for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Products sector is currently in the bottom 39% of over 250 Zacks industries, suggesting potential challenges for stocks in this category [8] - Ayr Wellness Inc., another company in the same industry, is expected to report a quarterly loss of $0.29 per share, reflecting a year-over-year change of +14.7%, with revenues projected at $111.05 million, down 5.3% from the previous year [9]

Group 1 - Biorestorative Therapies, Inc. reported a quarterly loss of $0.3 per share, which was better than the Zacks Consensus Estimate of a loss of $0.41, representing an earnings surprise of +26.83% [1] - The company posted revenues of $0.3 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 51.50%, compared to revenues of $0.09 million a year ago [2] - Over the last four quarters, Biorestorative Therapies has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] Group 2 - The stock has underperformed the market, losing about 1.4% since the beginning of the year, while the S&P 500 has gained 8.4% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to those expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.43 on $0.3 million in revenues, and -$1.76 on $0.93 million in revenues for the current fiscal year [7] Group 3 - The Zacks Industry Rank for Medical - Biomedical and Genetics is currently in the bottom 43% of over 250 Zacks industries, indicating potential challenges for stocks in this sector [8] - The estimate revisions trend for Biorestorative Therapies was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market [6]

Stryker (SYK) came out with quarterly earnings of $3.13 per share, beating the Zacks Consensus Estimate of $3.06 per share. This compares to earnings of $2.81 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of +2.29%. A quarter ago, it was expected that this medical device maker would post earnings of $2.73 per share when it actually produced earnings of $2.84, delivering a surprise of +4.03%. Over the last four quarters, the c ...

Industry Overview - The cannabis industry has experienced a decline in overall projections, yet some companies are still achieving success in specific areas, suggesting potential for a market correction in marijuana stocks [1] - The current downtrend in marijuana stocks has been volatile, with brief moments of upward trading quickly followed by declines [1][2] Investment Sentiment - Investors are advised against chasing speculative patterns based on the hope of federal reform and continued profitability, as the risks remain high [2] - Despite the low sector performance, identifying top marijuana stocks for long-term investment is becoming increasingly attractive [2] Long-term Outlook - Long-term investing is a common strategy among those interested in marijuana stocks, driven by the industry's growth and popularity, which offers hope for future recovery [3] - The potential for recovery could serve as a significant turning point for many marijuana stocks [3] Company Highlights - **Ascend Wellness Holdings, Inc.**: Engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the U.S. Recently launched a revamped eCommerce ecosystem to enhance customer experience [4] - **FLUENT Corp.**: Cultivates and sells medical cannabis products across several states, including Florida and Texas [5] - **Ayr Wellness Inc.**: Involved in the cultivation and retail of cannabis products, recently amended a Limited Waiver Agreement related to financial reporting delays [9][7]

Industry Overview - Marijuana stocks are currently in a volatile state with limited upward movement, prompting shareholders to explore various strategies to turn a profit [1] - The lack of federal reform in the U.S. and similar legal frameworks in other global regions are significant barriers, with better laws being essential for recovery [2] - Optimism exists within the industry, as companies are finding ways to maintain operations and profitability despite challenges [2][3] Company Highlights - **Ayr Wellness Inc.**: The company has extended its limited waiver agreement with senior noteholders until July 18, 2025, providing additional time for negotiations and strategic options to strengthen its capital structure [4][6] - **Verano Holdings Corp.**: Recently appointed James Leventis as Chief Strategy and Compliance Officer, aiming to enhance the company's strategic leadership [7][9] - **Glass House Brands Inc.**: Announced preferred equity refinancing on July 16, replacing existing Series B and Series C Preferred Stock with Series E Preferred Stock, effectively canceling the previous series [10][12]

Financial Performance - Taysha Gene Therapies reported a quarterly loss of $0.08 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.10 per share a year ago [1] - The company posted revenues of $2.3 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 9.62%, but down from $3.41 million year-over-year [2] - Over the last four quarters, Taysha Gene Therapies has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2][1] Stock Performance - Taysha Gene Therapies shares have increased approximately 37% since the beginning of the year, significantly outperforming the S&P 500's gain of 0.2% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.08 on revenues of $1.93 million, and for the current fiscal year, it is -$0.34 on revenues of $7.96 million [7] - The estimate revisions trend for Taysha Gene Therapies is mixed, which may change following the recent earnings report [6] Industry Context - The Medical - Generic Drugs industry, to which Taysha Gene Therapies belongs, is currently ranked in the bottom 24% of over 250 Zacks industries, indicating potential challenges ahead [8]

Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -14.29%. A quarter ago, it was expected that this company would post a loss of $0.03 per share when it actually produced a loss of $0.06, delivering a surprise of -100%. It will be interesting to see h ...